Data On Avicena’s Drug Candidate HD-02 Presented At The 2007 World Congress On Huntington’s Disease
Nov 20th 2007Drug InformationClinical Trials
Avicena Group, Inc. (OTCBB: AVGO), a late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today that Drs. Steven Hersch and Diana Rosas presented results regarding the Company’s novel Huntington’s disease treatment candidate HD-02 at the 2007 World Congress on Huntington’s Disease in Dresden, Germany. Drs. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
